

New Medicines Decisions for December 2025

maralixibat oral solution (Livmarli®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2806	for use in patients whose condition has not responded to standard of care medicines.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	19/02/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9630/maralixibat-livmarli-2nd-resub-final-aug-2025-amended-071125-for-website.pdf>

delgocitinib cream (Anzupgo®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2817	Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	17/04/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9635/delgocitinib-anzupgo-final-nov-2025-for-website.pdf>

New Medicines Decisions for December 2025

leniolisib film-coated tablet (Joenja®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2836	treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	19/02/2026
Other Decision Specified : Ultra-Orphan Initial Assessment				
Web Link : https://scottishmedicines.org.uk/media/9633/umar-leniolisib-joenja-final-nov-2025-for-website.pdf				

givinostat oral suspension (Duvyzat®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2856	treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. SMC restriction: Patients who are ambulant when they initiate givinostat treatment; this includes patients who are ambulant when they initiate givinostat and become non-ambulant during treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	19/02/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9636/givinostat-duvyzat-final-nov-2025-for-website.pdf				

New Medicines Decisions for December 2025

progesterone soft vaginal capsules (Prometrium®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2869	the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	19/02/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9631/progesterone-prometrium-abb-final-nov-2025-for-website.pdf>

amivantamab concentrate for solution for infusion (Rybrevant®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2878	in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	08/12/2025	19/02/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9634/amivantamab-rybrevant-resub-final-nov-2025-for-website.pdf>

New Medicines Decisions for December 2025

trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2888	treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.	Not routinely available as not recommended for use in NHS Scotland	08/12/2025	19/11/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9632/trastuzumab-deruxtecan-enhertu-non-sub-final-nov-2025-for-website.pdf				

iptacopan hard capsules (Fabhalta®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2889	treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated.	Not routinely available as not recommended for use in NHS Scotland	08/12/2025	19/11/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9629/iptacopan-fabhalta-non-sub-final-nov-2025-for-website.pdf				